Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

14.11.13	Lilly Reveals Significant Global Insulin Manufacturing Capacity Investments (RTTNews)
25.10.13	Lilly: FDA Approves Addition To CIALIS Product Label - Quick Facts (RTTNews)
24.10.13	AGN's Filler Gets FDA Green Light, ADXS, CYTR On Watch, IMMU On The Move (RTTNews)
23.10.13	Pre-market Movers For Oct 23 (BA, LLY, FB, COLE, GLW, CAT, NFLX, BRCM, CREE) (RTTNews)
23.10.13	Eli Lilly Ups Annual EPS View After Q3 Results Top Estimates (RTTNews)
23.10.13	FDA Grants Lilly's Ramucirumab Priority Review For Advanced Gastric Cancer (RTTNews)
23.10.13	Lilly Q3 Profit Down, Yet Beats Street; Tightens FY Earnings View - Quick Facts (RTTNews)
22.10.13	Jackson Tai Elected to Lilly Board of Directors (PR Newswire)
22.10.13	Jackson Tai Elected to Lilly Board of Directors (PR Newswire)
21.10.13	Lilly Declares Fourth-Quarter 2013 Dividend (PR Newswire)
16.10.13	Awareness Programs, Restructuring Efforts, Conference Calls, Marketing Authorization Withdrawal and Clinical Trial Commencement - Research Report on Lilly, Teva, Elan, Zoetis, and Boston Scientific (PR Newswire)
15.10.13	Under AAAResearchReports.com Microscope: Eli Lilly & Co., Bristol-Myers Squibb Co., Allergan Inc., and Endo Health Solutions Inc. (PR Newswire)
15.10.13	Lilly Confirms Date and Conference Call for Third-Quarter 2013 Financial Results Announcement (PR Newswire)
09.10.13	Lilly's Global Day of Service Supports Indy DO Day Initiative (PR Newswire)
03.10.13	Pre-market Movers For Oct 3 (LLY, TSLA, BBRY, CEVA, ANGI) (RTTNews)
03.10.13	Eli Lilly Reports Results From Phase III REGARD Trial Of Ramucirumab (RTTNews)
03.10.13	Lilly Sees New Product Launches In 2014, To Return $5 Bln More To Shareholders (RTTNews)
03.10.13	Single-Agent Ramucirumab Significantly Improves Overall Survival In Advanced Gastric Cancer Patients (PR Newswire)
03.10.13	Lilly Confirms Near-term Goals; To Buyback $5 Bln Of Shares - Quick Facts (RTTNews)
03.10.13	Lilly details progress on achieving strategic business goals and its advancing pipeline to investment community (PR Newswire)
01.10.13	Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year (PR Newswire)
01.10.13	Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly, Pfizer, Novartis, Sanofi, and AstraZeneca (PR Newswire)
30.09.13	Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013 (PR Newswire)
30.09.13	Eli Lilly Says Disappointed With CMS Decision To Deny Patient Access To Amyvid (RTTNews)
30.09.13	Lilly Disappointed Over CMS' Patient Access Denial To Beta-amyloid Imaging Agent (RTTNews)
30.09.13	Drug Approvals, Trial Results, and Collaboration- Research Report on Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, AbbVie, and GSK (PR Newswire)
28.09.13	Lilly Disappointed In Medicare Decision To Deny Patient Access To Amyvid (RTTNews)
28.09.13	Lilly Disappointed in Medicare Decision to Deny Appropriate Patient Access to Beta-Amyloid Imaging Agents, Including Amyvid™ (Florbetapir F 18 Injection), Despite Support From Experts, Patients and... (PR Newswire)
26.09.13	Lilly: Ramucirumab Meets Goal In Stomach Cancer, Misses In Breast Cancer (RTTNews)
26.09.13	Pre-market Movers For Sept 26 (FB, HTZ, LLY, FLOW, USAK, KBIO, WPRT) (RTTNews)
26.09.13	Lilly Reports Positive Patient-reported Health Outcomes From Dulaglutide Trial (RTTNews)
26.09.13	Data Presented at 49th EASD Annual Meeting Show Treatment with Lilly's Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes (PR Newswire)
26.09.13	Lilly: Ramucirumab Late-stage Gastric Cancer Study Meets Primary Endpoint (RTTNews)
26.09.13	Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint (PR Newswire)
25.09.13	Drug Recommendations, Presentations, Marketing Authorizations, and Board Appointments - Research Report on Johnson & Johnson, Lilly, Sanofi, GSK, and Pacira (PR Newswire)
24.09.13	Boehringer, Eli Lilly Report Results From Linagliptin Trials In Type 2 Diabetes (RTTNews)
24.09.13	Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes (PR Newswire)
20.09.13	Conference Call, Presentation of Drug Trial Results, Breakthrough Therapy Designation, Positive Results, and Drug Revival - Research Report on Johnson & Johnson, Lilly, GSK, Kythera, and Sanofi (PR Newswire)
19.09.13	Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery (PR Newswire)
17.09.13	Critical Alerts For Time Warner, Juniper Networks, Eli Lilly, Cliffs Natural Resources, and T-Mobile Released By InvestorsObserver (PR Newswire)
17.09.13	Pre-Market Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Health Solutions Inc., and Allergan Inc. (PR Newswire)
17.09.13	Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting (PR Newswire)
17.09.13	Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) (PR Newswire)
09.09.13	Event, FDA Approval, Positive Results, Partnership, and Marketing Authorization - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Lilly, and GSK (PR Newswire)
02.09.13	Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and Novartis (PR Newswire)
29.08.13	Humana And Lilly Form Research Collaboration - Quick Facts (RTTNews)
29.08.13	Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes (PR Newswire)
29.08.13	Acquisitions, Dividends, and Positive Data - Research Report on Onyx, Johnson & Johnson, Medtronic, Lilly, and Incyte (PR Newswire)
28.08.13	Dr. Marschall S. Runge Elected to Lilly Board of Directors (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

mehr

06:09		Novartis-Aktie: Novartis muss sich erneut Schmiergeld-Vorwürfen stellen
27.12.24		Anleger in New York halten sich zurück: Dow Jones beendet die Freitagssitzung im Minus
27.12.24		BioNTech und Pfizer zahlen Milliardenbetrag für Impfstoffvergleich in USA - BioNTech-Aktie fester
27.12.24		Optimismus in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
27.12.24		SLI-Handel aktuell: Zum Handelsende Gewinne im SLI
27.12.24		Freitagshandel in Frankfurt: LUS-DAX zeigt sich letztendlich fester
27.12.24		Börse Frankfurt: DAX zum Handelsende auf grünem Terrain
27.12.24		Börse Europa: Euro STOXX 50 verbucht zum Ende des Freitagshandels Zuschläge